JPRN-jRCT2031230275招募中Unknown
Special Drug Use-Results Survey (All-Case Surveillance) to Investigate Safety and Effectiveness in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Empaveli in the Post-Marketing Clinical Use in Japan - PEG_PNH JPN PMS
Shimmoto Naoki0 个研究点目标入组 100 人开始时间: 2023年8月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients with PNH who received Empaveli in Japan from the date of product launch to 31 May 2028 or until the approval conditions are lifted.
排除标准
- •Not applicable.
研究者
相似试验
进行中（未招募）
不适用
Protocol Number; CAIN457L1401JPRN-jRCT2031210589Toshiya Sugimoto35
已完成
不适用
Special Drug Use-Results Survey for Long-term Use of XEPLION TRI Aqueous Suspension for IM Injection 175 mg, 263 mg, 350 mg, and 525 mg SyringeSchizophreniaJPRN-UMIN000042033Janssen Pharma990
已完成
不适用
Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy)ovarian cancer aggravated after chemotherapyJPRN-UMIN000015902Janssen Pharmaceutical K.K.500
已完成
不适用
A Study of TAK-660 in surgical procedures for people with hemophilia AHemophilia AJPRN-jRCT2031210173Contact for Clinical Trial Information17
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3